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Background: Stress and anxiety-related behaviors are seen in many organisms. Studies have shown that in humans
and other animals, treatment with selective serotonin reuptake inhibitors (e.g. fluoxetine) can reduce anxiety and
anxiety-related behaviors. The efficacies and side effects, however, can vary between individuals. Fluoxetine can
modulate anxiety in a stereospecific manner or with equal efficacy regardless of stereoisomer depending on the
mechanism of action (e.g. serotonergic or GABAergic effects). Zebrafish are an emerging and valuable translational
model for understanding human health related issues such as anxiety. In this study we present data showing the
behavioral and whole brain transcriptome changes with fluoxetine treatment in wild-derived zebrafish and suggest
additional molecular mechanisms of this widely-prescribed drug.
Results: We used automated behavioral analyses to assess the effects of racemic and stereoisomeric fluoxetine on
male wild-derived zebrafish. Both racemic and the individual isomers of fluoxetine reduced anxiety-related
behaviors relative to controls and we did not observe stereospecific fluoxetine effects. Using RNA-sequencing of
the whole brain, we identified 411 genes showing differential expression with racemic fluoxetine treatment. Several
neuropeptides (neuropeptide Y, isotocin, urocortin 3, prolactin) showed consistent expression patterns with the
alleviation of stress and anxiety when anxiety-related behavior was reduced with fluoxetine treatment. With gene
ontology and KEGG pathway analyses, we identified lipid and amino acid metabolic processes, and steroid
biosynthesis among other terms to be over-enriched.
Conclusion: Our results demonstrate that fluoxetine reduces anxiety-related behaviors in wild-derived zebrafish and
alters their neurogenomic state. We identify two biological processes, lipid and amino acid metabolic synthesis that
characterize differences in the fluoxetine treated fish. Fluoxetine may be acting on several different molecular
pathways to reduce anxiety-related behaviors in wild-derived zebrafish. This study provides data that could help
identify common molecular mechanisms of fluoxetine action across animal taxa.
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Many organisms experience stress from natural sources
such as territory defense, food competition, resource ac-
quisition and exploration. In humans persistent extreme
responses to stressful and anxiety-inducing situations or
the inability to cope with such scenarios is a characteris-
tic of an anxiety disorder [1]. Pharmacological studies
indicate that anxiety and anxiety-related behaviors are* Correspondence: ryan_wong@ncsu.edu
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reproduction in any medium, provided the orassociated with dysregulation of at least one of several
major neurotransmitter systems in the brain: serotoner-
gic (serotonin), GABAergic (gamma-aminobutyric acid),
catecholaminergic (noradrenaline, dopamine) and gluta-
matergic (glutmate) systems [2,3]. Efficacies of various
anxiolytic compounds, however, vary between individ-
uals (both human and animal models) [4]. The extent to
which this can be attributed to the nonselective or pleio-
tropic molecular aspects of the anxiolytic is unknown.
Selective serotonin reuptake inhibitors (SSRIs) are typ-
ically the first-line drugs prescribed for the alleviation of
anxiety disorders in humans [5]. SSRI compounds (e.g.,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transporter thus allowing for serotonin levels to remain
high for longer periods of time in the synapse. Fluoxet-
ine (tradename: Prozac) is a racemic mixture where both
the R and S isomers effectively inhibit the serotonin
transporter [6-10] and has also been demonstrated to
have anxiolytic effects in rodents and fish [11,12]. While
SSRIs are known to modulate serotonin levels, it has
been shown that they also modulate production of
neurosteroids (e.g. allopregnanolone) that act as modula-
tors of GABA receptors [13-16]. In fluoxetine, S-
fluoxetine induces greater allopregnanolone production
in rodent brains than the R isomer [6,14]. Increasing
allopregnanolone levels in rodents has been associated
with decreases in aggression and anxiety [6,15,17-23]. In
addition, SSRIs also affect various neuropeptide levels
(e.g., neuropeptide Y, oxytocin, arginine vasopressin),
which independently can modulate stress and anxiety
levels [24]. Our laboratory has shown fluoxetine can
affect expression of neuropeptide genes in teleosts [25].
Hence SSRIs appear to affect many systems and under-
standing the full extent of changes in molecular mecha-
nisms underlying fluoxetine mediated reduction in
anxiety and stress is needed.
To understand the mechanisms underlying stress and
anxiety, animal models used are highly inbred (i.e.,
domesticated) or selectively bred to exhibit extreme be-
havioral and physiological responses to stressful and
anxiety-inducing contexts [2,11,26-29]. Although ro-
dents have been primarily used as animal models for
anxiety [2,26], zebrafish (Danio rerio) is an emerging sys-
tem and valuable translational model for understanding
stress and anxiety-related behaviors [30-35]. Similar to
rodents, highly inbred lines of zebrafish show differences
in baseline levels of stress and anxiety as well as re-
sponses to anxiolytics [2,4,11,12,36,37]. Zebrafish share
similar neurochemistry, and behavioral and physiological
responses to both anxiolytic and anxiogenic drugs as
mammals [11,30,31]. Several neurotransmitter systems
thought to be modulated in stress and anxiety (e.g., cate-
cholamines, serotonin) in mammals are also described in
zebrafish [32,38,39]. Zebrafish possess genes that encode
serotonin transporters homologous to those of tetra-
pods, and the transporters have been shown to transport
serotonin across cell membranes and the activity can be
reduced with a SSRI in vitro [40]. Further, SSRI binding
kinetics to the serotonin transporter in teleosts are
similar in magnitude to rats [41]. Adult domesticated
zebrafish also show reduced anxiety-related behaviors
and cortisol levels when treated with fluoxetine [11].
Larval zebrafish treated with fluoxetine show changes in
molecular pathways associated with stress response [42],
but very little is known of the gene expression changes
in adults. Hence, in addition to the zebrafish system’samenability for genetic manipulations and high through-
put drug screening [43-45], the zebrafish represents a
powerful model to explore molecular mechanisms of
stress and anxiety-related behaviors.
In this study we assess the effects of chronic fluoxetine
treatment on behavior and the neural transcriptome of
adult wild-derived male zebrafish (High Stationary Be-
havior line, HSB, [29]). The HSB line shows consistently
high levels of stress and anxiety-related behaviors across
multiple assays [29]. Given documented stereospecific
fluoxetine effects on aggressive behavior and anxiety-
mediated neurochemical pathways in rodents [14,21], we
test whether anxiety-related behaviors can be modulated
stereospecifically in zebrafish by administering racemic,
R-fluoxetine, and S-fluoxetine. To analyze the under-
lying mechanism of fluoxetine-induced anxiolytic effects
of behavior, we use RNA-sequencing and test for whole-
brain differential expression of protein-coding genes
between racemic fluoxetine treatment and control.
Through both behavioral and gene expression analyses,




Male zebrafish from our selectively bred High Stationary
Behavior line (see [29] for line characteristics) were
subjected to one of four treatments: a racemic mixture
of fluoxetine (n = 30), R-fluoxetine (n = 12), S-fluoxetine
(n = 12), or our solvent (water) as a control (n = 42).
Studies in other teleosts have shown that waterborne
fluoxetine enters the brain and has an approximate half
life of nine and three days in the fish and water
containing fish, respectively [46-48]. Testing of the ra-
cemic and stereoisomer treatment groups were sepa-
rated by two months.
The first set of experiments involved treating zebrafish
with a racemic fluoxetine mixture or the vehicle control.
Treatment duration and racemic fluoxetine concentra-
tion follow a previously established protocol [11]. Briefly,
fish were chronically treated with 100 μg/L of racemic
fluoxetine (Sigma). As it has been previously demon-
strated that two weeks of exposure to racemic fluoxetine
alters behavior and cortisol levels [11], we assessed
whether behavioral changes can be detected on a shorter
time scale and thus behaviorally tested fish (n = 12, see
below) treated for one week. However, to be consistent
with methods in the literature and to make our gene ex-
pression results comparable with previous studies, we
treated a different set of fish (n = 18) with racemic flu-
oxetine for two weeks. During treatment, the fish were
housed in 2 L tanks in groups of six with constant aer-
ation and fed ad libitum daily with commercial food
(Tetramin). Every two days, we replaced all of the
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used for normal housing) containing 100 μg/L racemic
fluoxetine. Control fish (n = 42) underwent identical
procedures with the exception that the solvent (water)
was added to the tanks. For the second set of experiments
we administered isomers of fluoxetine and controls to a
different set of fish. Fish treated with a stereoisomer of flu-
oxetine were handled exactly the same way as above, but
were treated at a concentration of 33 μg/L for two weeks.
As no previous study has administered isomers of fluoxet-
ine in teleosts, our goal was to identify a dose that would
maximize the opportunity to observe differences in the
behavioral effects of the two isomers in the same manner
conducted in rodents [21]. We determined that 33 μg/L is
a biologically relevant dose through pilot dose-response
analysis where we treated individuals for two weeks as
described above but at four different concentrations
(Additional file 1: Figure S1). We experienced minimal
deaths and all fish consumed food during the treatment
period, which suggests all were in good health (final sam-
ple size: racemic fluoxetine (n = 28), R-fluoxetine (n = 11),
S-fluoxetine (n = 11), control (n= 37)).
A subset of fish were treated with racemic fluoxetine
(n=18) or water (control, n = 18) but did not undergo
behavioral testing. These fish were decapitated and
brains removed and stored in RNAlater (Ambion) until
processing for either RNA-sequencing or qRT-PCR (see
below). The remaining racemic fluoxetine treated fish,
those treated with a fluoxetine isomer and control fish
were behaviorally tested (see below). All fish used in this
study were sexually mature, 7 – 11 months old, and five
generations removed from the wild with the exception
of a subset of males used in the qRT-PCR experiment,
which were sixth generation.
RNA-sequencing analysis
Using RNA-sequencing, we quantified whole-brain tran-
scriptome levels in male zebrafish (five generations
removed from the wild) treated with a racemic mixture
of fluoxetine (n = 9) and control animals (n =10). We
extracted RNA using RNeasy Plus Mini Kit (Qiagen)
according to the manufacturer’s protocol. Since we
wanted to assess a general effect of fluoxetine on gene
expression, we pooled one microgram of total RNA from
each individual in a treatment (e.g. one pooled sample
for fluoxetine-treated and control fish). RNA quality was
assessed with an Agilent 2100 Bioanalyzer (Agilent) and
all samples had RNA integrity numbers (RIN) above 8.5.
RNA samples were then submitted to the Genomic
Sciences Laboratory at North Carolina State University,
for cDNA library preparation (TruSeq RNA Sample Prep
v2, Illumina) and 72 bp single-end RNA-sequencing
(Illumina GAIIx). Following a balanced block design
[49], both samples were multiplexed and run acrossthree lanes. During analysis we combined reads across
all lanes that passed default quality control filters
(Illumina), which generated approximately 30.6 million
reads for each of the control and fluoxetine-treated
groups. Reads were aligned to the Danio rerio genome (as-
sembly Zv9 [35], release 68) using GSNAP [50] with de-
fault parameters. We used Cufflinks (ver 2.0.1, [51-53]) to
assess differential expression of protein-coding genes
between control and fluoxetine-treated fish employing
the program’s multi-read and fragment bias correction.
We used gProfiler [54,55] to determine significantly
over-enriched Gene Ontology (GO) terms and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways.
In Cufflinks and gProfiler we utilized the default false
discovery rate (FDR) corrections. Statistical significance
was assessed when pFDR-corrected < 0.05.
Real-time PCR validation analysis
We assessed the expression of seven genes (prl2, npy,
oxtl, slc6a4a, slc6a4b, slc6a11, ucn3l) associated with
anxiety-like behaviors in other organisms, two genes
showing more than two fold differences (isg15, nrbf2) in
expression between treatments, and one housekeeping
gene (ef1a) using quantitative reverse transcriptase PCR
(qRT-PCR). Of these genes prl2, npy, oxtl, slc6a11,
ucn3l, isg15, and nrbf2 were differentially regulated with
RNA-sequencing (see below). We used 12 fish treated
with racemic fluoxetine and 12 control fish. Six fish in
each treatment group were independent from those used
in RNA-seq analysis (six generations removed from the
wild). Total RNA from all brains was extracted following
the same protocol used for RNA-sequencing prepara-
tions (see above). Genomic DNA was removed by col-
umn filtration according to manufacturer’s protocol
(RNeasy Plus Mini kit, Qiagen). We subsequently quan-
tified the RNA using Quant-iT RiboGreen (Invitrogen).
Eight microliters of total RNA from each individual was
reverse transcribed into cDNA using SuperScript III
First-Strand Synthesis System for qRT-PCR (Invitrogen)
according to modified manufacturer’s protocol where
the sample was primed with both random hexamers and
oligo(dT)20 primers. The cDNA was then purified using
Amicon Ultracentrifugal filters (Millipore) according to
the manufacturer’s protocol [56-58]. The resulting puri-
fied samples were topped off to 100 μl total volume with
Nuclease-Free water (Ambion).
The qRT-PCR was run on an ABI 7900HT Fast Real-
Time PCR system (Applied Biosystems) using SYBR green
detection chemistry (SYBR Select, Applied Biosystems).
The primers were designed using Primer-BLAST (NCBI)
and primers either spanned exon-exon junctions or the
amplicon spanned exons where the intron region was over
one kilobase. Each sample was run in triplicate (see














































































Figure 1 Behavioral measures after drug treatment. A) Amount
of time spent in the top half of the tank, latency to the top half of
the tank and stationary behavior for fish treated with racemic
fluoxetine (white) or controls (grey). B) Amount of time spent in the
top half of the tank, latency to the top half of the tank and
stationary behavior for fish treated with R isomer (red), S-isomer
(brown) or control (grey). Error bars represent standard error.
*, p < 0.05; **, p < 0.01; ***, p < 0.001.
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ized gene expression relative to a housekeeping gene
(ef1a) and assessed differential expression using commer-
cial software (REST 2009 [59], Qiagen). Our housekeeping
gene has been shown to be stable across sex, tissue types,
age, and chemical treatment in zebrafish [60]. Normalizing
gene expression to total input RNA produced similar re-
sults (Additional file 3: Figure S2). We predicted that
qRT-PCR results would follow the RNA-sequencing
results and assessed and reported significance using one-
tail p-values.
Behavioral assay
Fish exposed to a stereoisomer of fluoxetine and control
fish were tested in the Novel Tank Diving Test (NTDT)
using established protocols [11,29] to assess changes in
anxiety-related behaviors. Briefly, fish were placed in a
15.2 × 27.9 × 22.5 × 7.1 cm (height × top × bottom ×
width) trapezoidal tank (Aquatic Ecosystems) filled with
1.4 L of system water. We video-recorded the behavior
of the fish for six minutes for later analysis using an ani-
mal tracking software package (TopScan Lite, Reston,
Virginia, USA). Fish treated with racemic mixture of flu-
oxetine (n = 12) and control fish (n = 12) were tested
for five minutes. All fish were five generations removed
from the wild. We report latency to enter the top half of
the tank, time spent in top half of the tank and station-
ary time. Stationary time is measured as the amount of
time the fish does not exceed a swimming speed of 0.1
cm/sec [29]. For fish that never entered the top half of
the tank we set the latency as the length of the trial. All
procedures and protocols in this study were approved by
the North Carolina State University Institutional Animal
Care and Use Committee.
Results and discussion
Fluoxetine reduces anxiety-related behavior but not
stereospecifically
An anxious state is inferred when an animal is placed in an
environment where it is conflicted with seeking out poten-
tial benefits with that of potential harm (e.g. approach and
avoidance) [2]. The approach-avoidance conflict premise is
the basis of many common measures of anxiety-related be-
havioral assays (e.g. open field test, elevated plus maze,
light-dark test) [2,61]. In zebrafish one ethologically rele-
vant behavior to potential danger is to swim to the bottom
substratum and after the threat has passed, the zebrafish
will swim back into the water column. The novel tank div-
ing assay used in this study measures behavioral levels of
stress and anxiety-related behaviors in zebrafish by
assessing latency to and time spent in the top half of the
tank [11,29]. In this study wild-derived zebrafish treated
with racemic fluoxetine spent significantly more time in
(t = -6.49, p = 2 × 10-6) and had a shorter latency to thetop half of the tank (t = 8.92, p = 1.38 × 10-8) compared to
the controls (Figure 1A). This suggests that fluoxetine
treatment reduced stress and anxiety-related behaviors in
male zebrafish. Our data are consistent with published
anxiolytic effects of fluoxetine in domestiecated
zebrafish and rodents [11,12]. Fluoxetine has also been
documented to alter locomotion [11,12], which could
confound interpretations of stress and anxiety levels. In
this study we did not observe significant differences in
locomotion time (i.e. stationary time (t-stat = 1.29, p =
0.21), Figure 1A) suggesting that in our experiment the
anxiolytic effect of fluoxetine is not likely to be a conse-
quence of reduced ability or motivation to swim.
While both isomers reduced stress and anxiety-related
behaviors, one was not more potent than the other.
There were no significant differences in time spent in
the top half of the tank between zebrafish treated with
R- or S- fluoxetine (t = 1.47, p = 0.16, Figure 1B), but
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the top than controls (F = 30.13, p = 8.31 × 10-8,
Figure 1B). Relatedly, fish treated with either isomer had
a shorter latency to enter the top half of the tank relative
to controls (F = 39.32, p = 5.5 × 10-9, Figure 1B) but
there were no stereospecific effects (t = 0.39, p = 0.7,
Figure 1B). Each fluoxetine isomer had minimal effects
on locomotor activity (F = 0.22, p = 0.8, Figure 1B). Our
data are consistent with the idea that given both
fluoxetine isomers exhibit similar pharmacodynamics in
inhibiting the serotonin transporter [6-10], there would
be no predicted differences in anxiolytic effects. Fluoxet-
ine, however, increases neurosteroid production (e.g.
allopregnanolone) in a stereospecific manner and this
has been proposed as an alternative mechanism of ac-
tion for anxiolytics in mammals [14,62]. Although we
did not see any stereospecific anxiolytic effects of fluox-
etine at the behavioral level, we have evidence that
steroidogenic molecular pathways in the brain are over-
represented with racemic treatment (Table 1 and 2, dis-
cussion below). Hence it is possible in zebrafish that
some anxiolytic mechanisms of fluoxetine include alter-
ation of both serotonin and neurosteroid levels.
Changes in gene expression consistent with alterations in
stress and anxiety levels
Neuropeptides have modulatory roles in a variety of be-
haviors including stress and anxiety. RNA-sequencing
analysis showed that several neuropeptides associated
with stress and anxiety in other studies were differen-
tially regulated with racemic fluoxetine treatment and
validated with qRT-PCR (Figure 2). Isotocin (oxtl, RNA-
sequencing: test statistic = -3.74, p = 0.014; qRT-PCR:
p = 0.034) and neuropeptide Y (npy, test statistic = -5.37,
p = 1.8 × 10-5; qRT-PCR: p = 0.045) showed significantly
higher expression in fluoxetine treated fish relative to con-
trols (Figure 2A, B). While isotocin is homologous to the
mammalian oxytocin, relatively little is known about
isotocin’s behavioral functions in fishes [63]. In wild-type
zebrafish, peripheral isotocin injection decreased the level
of fear response to a predator in a dose-dependent man-
ner [64], which suggests an anxiolytic effect. In rodents,
pharmacological manipulations, gene expression, and
transgenic animal studies have shown increases in oxyto-
cin and NPY levels are associated with reduced anxiety
[65-72]. Oxytocin is thought to affect many social beha-
viors in humans [73] including having anxiolytic effects
[74,75]. Interestingly, variants of NPY in humans are asso-
ciated with anxiety susceptibility [76] and zebrafish may
be an ideal system to explore this further.
Anxiety-related behavioral displays are often associ-
ated with a physiological stress response. The stress
response in teleosts has been well-described [77,78] and
the molecular mechanisms underlying the cortisol stressresponse in zebrafish are similar to mammals [33,79].
While we did not measure corticosteroid levels, the first
study administering fluoxetine to domesticated zebrafish
in the same paradigm used in this study found reduced
whole-body cortisol levels compared to controls [11]. At
the molecular level, urocortin 3 (ucn3l, part of the
corticotrophin-releasing hormone family) and prolactin
(prl2) were down-regulated with fluoxetine treatment in
both RNA-sequencing (ucn3l: test statistic = 3.99, p =
0.006; prl2: test statistic = 5.35, p = 1.98 × 10-5;
Figure 2C, D) and qRT-PCR analyses (ucn3l and prl2, p <
0.001, Figure 2C, D). Urocortin 1-3 interact with the cor-
ticotrophin system in the brain by binding to the same
receptors and can alter stress and anxiety [80-83]. Specif-
ically, central administration of urocortins has been shown
to be anxiogenic in rats [84-88]. The exact role of
urocortin 3 in mediating stress and anxiety is not well
understood as pharmacological and knock-out studies in
rodents produce inconsistent results [89-91]. Prolactin in
the brain is often associated with maternal behavior, but it
is also associated with stress coping [92-94]. Other teleosts
displayed elevated plasma prolactin levels in response to
stress [95,96], which is consistent with our results where
treatment with an anxiolytic reduced prl2 expression. It
should be noted that for the gene expression parts of
this study, we did not induce stress prior to brain
extraction and this may explain why more genes associ-
ated with a stress response were not differentially regu-
lated (Additional file 4: Table S2). Hence the reduction
of ucn3l and prl2 expression compared to the controls
is consistent with the fluoxetine-treated fish having
lower basal stress levels.
Neurotransmitter transporters have an important role in
maintaining neural activity. The gene coding for the
GABA transporter, slc6a11, was significantly down-
regulated in fluoxetine treated fish with RNA-sequencing
(test statistic = 6.06, p = 4.49 × 10-7, Figure 3A). Alteration
of GABA mediated signaling is one proposed causal
mechanism of anxiety and GABA transporter knockout
mice exhibit reduced anxiety- and depression-related be-
haviors [97]. Hence, lower expression of GABA trans-
porter is consistent with the finding that fluoxetine treated
fish had reduced stress and anxiety-related behaviors.
qRT-PCR validation showed mixed results where normal-
izing to a housekeeping gene showed significant differ-
ences between groups (p = 0.035, Figure 3A) but
normalizing to total RNA did not (t = 1.34, p = 0.096,
Additional file 3: Figure S2). The serotonin transporters
(slc6a4a and slc6a4b) showed no differences in expres-
sion between groups by RNA-sequencing (slc6a4a: test
statistic = 0.957, p = 0.855; slc6a4b: test statistic = 0.86,
p = 0.876; Figure 3B, C) or qRT-PCR (slc6a4a: p =
0.058; slc6a4b: p = 0.242; Figure 3B, C). This is consist-
ent with other studies in teleosts and rodents where
Table 1 Gene ontology analysis of differentially expressed genes
Gene ontology FDR corrected p-value






BP lipid metabolic process GO:0006629 1.62E-03 6.01E-07
BP lipid biosynthetic process GO:0008610 8.22E-03 5.75E-05
BP fatty acid metabolic process GO:0006631 8.77E-03 2.21E-04
BP very long-chain fatty acid metabolic process GO:0000038 7.78E-03 1.99E-03
BP fatty acid biosynthetic process GO:0006633 1.09E-02 4.35E-04
BP very long-chain fatty acid biosynthetic process GO:0042761 7.78E-03 1.99E-03
BP small molecule metabolic process GO:0044281 1.06E-02
BP organic acid metabolic process GO:0006082 1.56E-04 1.83E-02
BP oxoacid metabolic process GO:0043436 1.56E-04 1.83E-02
BP carboxylic acid metabolic process GO:0019752 5.22E-04 1.43E-02
BP single-organism biosynthetic process GO:0044711 2.24E-03
BP small molecule biosynthetic process GO:0044283 1.93E-03
BP organic acid biosynthetic process GO:0016053 2.86E-04
BP carboxylic acid biosynthetic process GO:0046394 2.86E-04
BP L-serine metabolic process GO:0006563 2.66E-02 2.66E-03
BP organonitrogen compound metabolic process GO:1901564 4.70E-02
BP organonitrogen compound biosynthetic process GO:1901566 1.88E-02
BP cellular amino acid metabolic process GO:0006520 2.27E-03
BP cellular amino acid biosynthetic process GO:0008652 2.54E-02
BP alpha-amino acid biosynthetic process GO:1901607 1.66E-02
BP serine family amino acid biosynthetic process GO:0009070 6.35E-03
BP response to virus GO:0009615 3.05E-03
BP monocarboxylic acid metabolic process GO:0032787 2.07E-03
BP monocarboxylic acid biosynthetic process GO:0072330 2.60E-03
BP steroid metabolic process GO:0008202 4.99E-02
BP cellular lipid metabolic process GO:0044255 4.82E-03
BP sterol metabolic process GO:0016125 1.21E-02
MF phosphorylase activity GO:0004645 4.24E-02 7.31E-03
MF glycogen phosphorylase activity GO:0008184 1.72E-02 2.95E-03
MF cofactor binding GO:0048037 3.24E-02
MF catalytic activity GO:0003824 3.19E-02
MF oxidoreductase activity GO:0016491 2.96E-03 1.43E-03
MF oxidoreductase activity, acting on CH-OH group of
donors
GO:0016614 8.66E-03
MF transferase activity, transferring acyl groups GO:0016746 9.02E-03
MF oxidoreductase activity, acting on paired donors, with
incorporation or reduction of molecular oxygen, NADH
or NADPH as one donor, and incorporation of one
atom of oxygen
GO:0016709 2.47E-02
BP Biological Process, MF Molecular Function, DEG all differentially expressed genes. Blank cells indicate p > 0.05.
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other than the serotonin transporter [42,98-101]. SSRIs
bind to serotonin transporters to inhibit their function,
however, SSRIs may not regulate the expression of thetransporter. Although several microarray studies focusing
on a specific brain region did not show significant differ-
ences in expression of the serotonin transporter gene with
fluoxetine treatment [98-101], we cannot rule out brain
Table 2 KEGG pathway analysis of differentially
expressed genes
KEGG Pathway FDR corrected
p-value
Fatty acid elongation 2.21E-02
Metabolic pathways 5.11E-04
Arachidonic acid metabolism 1.98E-03
Synthesis and degradation of ketone bodies 1.08E-02
Terpenoid backbone biosynthesis 4.36E-03
Glycine, serine and threonine metabolism 2.77E-02
Metabolism of xenobiotics by cytochrome P450 6.78E-03
Steroid biosynthesis 1.96E-09
Steroid hormone biosynthesis 1.27E-03
Wong et al. BMC Genomics 2013, 14:348 Page 7 of 13
http://www.biomedcentral.com/1471-2164/14/348region specific regulation in zebrafish. Two genes (isg15,
nrbf2) showed greater than two fold differences in expres-
sion between groups in RNA-sequencing (Figure 3D, E,
Additional file 4: Table S2) but were not validated by
qPCR (isg15: p = 0.1; nrbf2: p = 0.072). The housekeeping
gene, elongation factor 1-alpha (ef1a) showed no signifi-












































































Figure 2 RNA-sequencing and qRT-PCR expression of select genes wi
(B) neuropeptide Y, (C) urocortin 3, and (D) prolactin. In each panel left and
(fragments per kilobase per million reads, FPKM) and qRT-PCR (expression r
qRT-PCR gene expression was normalized to a housekeeping gene. Grey an
Error bars represent 95% confidence intervals. *, p < 0.05; **, p < 0.01; ***, p(test statistic = 0.258, p = 0.976, Figure 3F) or qRT-PCR
(Additional file 3: Figure S2). Overall, 80% of the genes we
examined by qRT-PCR showed consistent expression pat-
terns as RNA-sequencing, which is a rate consistent with
other transcriptome studies [102,103]. There was a trend
for a positive correlation between RNA-sequencing and
qRT-PCR expression levels across all genes (n = 10, r =
0.49, p = 0.072). However, when excluding genes (isg15,
nrbf2) that did not show consistent expression patterns
between RNA-sequencing and qRT-PCR, there was a sig-
nificant positive correlation (n = 8, r = 0.88, p = 0.002).
Identification of global transcriptome changes and
related pathways
Of the 26,585 protein-coding genes analyzed, 411 were
differentially regulated with racemic fluoxetine treatment
(Figure 4, Additional file 4: Table S2). In racemic fluoxet-
ine treated fish, 167 and 244 genes were up- and down-
regulated, respectively. Gene ontology (GO) analysis of
all differentially expressed genes reveal that terms re-
lated to lipid (p = 0.001) and small molecule metabolism
(p = 0.01) were significantly over-enriched (Table 1).









































































th racemic fluoxetine treatment. Gene expression of (A) isotocin,
right graphs represent quantification from RNA-sequencing
atio: gene expression in fluoxetine treatment / control), respectively.
































































































































































































Figure 3 RNA-sequencing and qRT-PCR expression of select genes with racemic fluoxetine treatment. Gene expression of (A) GABA
transporter, (B) serotonin transporter A, (C) serotonin transporter B, (D) ISG15 ubiquitin-like modifier, (E) nuclear receptor binding factor 2, and
(F) elongation factor 1-alpha. In each panel left and right graphs represent quantification from RNA-sequencing (fragments per kilobase per
million reads, FPKM) and qRT-PCR (expression ratio: gene expression in fluoxetine treatment / control), respectively. qRT-PCR gene expression was
normalized to a housekeeping gene. Grey and white bars represent control and fluoxetine treatment, respectively. Error bars represent 95%
confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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http://www.biomedcentral.com/1471-2164/14/348expression in the GO analysis, amino acid and lipid
metabolic processes were up-regulated and down-
regulated, respectively, with fluoxetine treatment
(Table 1). These data suggest that male zebrafish treated
with fluoxetine (i.e., reduced anxiety and stress levels)
may be shifting macromolecule resources from energy
(e.g. lipid) to enzymatic (e.g. amino acid) processes in
the brain. It is well known that individuals will change
foraging habits in the presence of predators [104,105]
and it is plausible that less anxious zebrafish seek out
foods higher in protein content. While we fed thefluoxetine-treated and control groups ad libitum future
studies should assess for differences in food consump-
tion or diet preference. An equally likely hypothesis is
that individuals with higher stress and anxiety levels
have disrupted neurosteroid levels - possibly due to al-
tered precursor activity. Of note, fish used in this study
were selectively bred to exhibit high levels of stress and
anxiety behaviors and hence control fish are presumed
to have high levels of stress and anxiety [29]. Highly
stressed and anxious (e.g., control) fish have up-





















Figure 4 Volcano plot of all protein-coding genes analyzed by
RNA-sequencing. Genes differentially expressed with p < 0.05 after
correcting for false discovery rate are in orange. Genes with a p >
0.05 after correcting for false discovery rate are in black. Any point
above 15 on the y-axis has a p < 5 x 10-15.
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http://www.biomedcentral.com/1471-2164/14/348may lead to altered neurosteroid production (via precur-
sor availability). We acknowledge that transcriptome
wide patterns are challenging to interpret and in this
study we can only speculate on the precise roles of lipid
and amino acid metabolism in stress and anxiety. It is
also possible that by utilizing the whole brain, we may
not be able to detect some pathways that are differen-
tially expressed in specific regions. It should be noted,
however, that whole-brain transcriptome studies still
provide important insights into the molecular mecha-
nisms of sex differences and a variety of social behaviors
[56,106-114]. Future studies should use transgenic
zebrafish or pharmacologically alter expression levels to
better characterize the role of a gene. Complementary
studies could also assess localized differential expression
patterns of “candidate” genes across the brain via
neurohistochemical techniques [115-117] to assist in
identifying candidate brain regions for transcriptomic
analyses. Alternatively, using zebrafish with naturally
high and low stress and anxiety-related behavioral levels
(e.g., HSB, LSB [29]) will provide an opportunity to test
for similar sorts of transcriptome changes in a non-
pharmacological context and is currently underway in
our laboratory.
Using an alternative database to analyze global tran-
scriptome changes that has associations with pathways,Kyoto Encyclopedia of Genes and Genomes (KEGG
[118,119]), resulted in largely similar over-represented
pathways as GO analysis (Table 2). Amino acid pathways
(glycine, serine, and threonine, p = 5.11 × 10-4) and lipid
related pathways (fatty acid elongation, p = 0.022) were
over-represented (Table 2). Notably, steroid (p = 1.96 ×
10-9) and steroid hormone (p = 0.001) biosynthesis path-
ways were also over-represented (Table 2). While we did
not measure steroid levels in this study, in male goldfish
treated with fluoxetine, there was an increase in estradiol,
decrease in testosterone, and no changes in luteinizing or
growth hormone serum levels but how these changes re-
late to anxiety-related behaviors was not discussed [120].
Neurosteroids (e.g. allopregnanolone) are implicated as
potential mediators of anxiety in mammals [13-15,18,121].
Fluoxetine can increase neurosteroid content and S-
fluoxetine increases allopregnanolone levels more effect-
ively than the R isomer [13,14,21]. Allopregnanolone
reduces anxiety in rodents and has a similar efficacy as
fluoxetine [122-125]. As we see reduction in anxiety-
related behaviors (Figure 1) and over-representation of
steroid hormone pathways (Table 2) in the brain with
fluoxetine treatment, it is possible that the anxiolytic
effects seen in this study are due to changes in
neurosteroid content.
Few studies have examined transcriptome level
changes in gene expression with fluoxetine treatment in
teleosts. One study has examined the effects of fluoxet-
ine treatment on differential gene expression in whole
body larval zebrafish through microarrays [42]. Of genes
we found differentially expressed in adult male whole-
brain zebrafish, only three of these genes (fkbp5, itm2cb,
and an unannotated gene) were also differentially
expressed in larval zebrafish [42]. Fluoxetine is known to
have age-dependent effects in mammals and it is pos-
sible that we are observing molecular evidence of this in
zebrafish [126-128]. It should be noted though, that
changes in membrane protein activity and/or compos-
ition (e.g. fkbp5, itm2cb) may be a common mechanism
of fluoxetine action across the lifecycle. Interestingly, in
a microarray study identifying hypothalamic differential
gene expression in female goldfish treated with fluoxet-
ine, we observed only three genes (trib3, oxtl, mbpb) that
were similarly differentially regulated in our study. It is
possible that this minimal amount of overlap between
lists of genes differentially regulated is due to sex or re-
gional specificity. Hypothalamic isotocin levels de-
creased with fluoxetine treatment in female goldfish
[98] but showed no expression differences in male tel-
encephalon [120]. It should be noted that neither of the
studies utilizing fluoxetine-treated goldfish [98,120] or lar-
val zebrafish [42] measured anxiety-related behavior. Sur-
prisingly, the lack of a large overlap of differentially
expressed genes with fluoxetine treatment was also found
Wong et al. BMC Genomics 2013, 14:348 Page 10 of 13
http://www.biomedcentral.com/1471-2164/14/348between mice and rats with genomic analyses [99-101].
While there may be species- and brain region-specific
effects of fluoxetine, uncovering potential universal mech-
anisms of action of fluoxetine will need to utilize a more
comprehensive comparative approach.
Conclusions
In this study we present data from both behavioral and
molecular levels showing that fluoxetine alters stress and
anxiety-related behaviors in wild-derived male zebrafish.
Racemic and stereoisomers of fluoxetine reduce anxiety-
related behaviors as indicated by drug treated fish
spending more time in the top half of the tank. There
were no stereoisomer effects on behavior but these ef-
fects were not tested at the molecular levels where it is
possible that GABAergic and serotonergic activity were
altered. In the small sampling of “candidate” neuropep-
tides (npy, oxtl, prl2, ucn3l) linked to stress and anxiety
in the literature, our gene expression results were con-
sistent with fluoxetine-induced changes at the molecular
level in other model systems. Larger scale analyses reveal
that lipid and amino acid metabolic processes and steroid
biosynthesis are disproportionately influenced. Changes in
lipid, amino acid and neurosteroid utilization in the brain
may be characteristic of fluoxetine treatment and, by ex-
tension, stress and anxiety.
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